Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Share your work at an international, multidisciplinary congress designed to amplify voices like yours!
See you in Munich to network and share ideas at this dedicated event for the breast cancer community
Join a key gathering for oncology professionals across the Asia-Pacific region, bringing together top experts, researchers, and healthcare providers to advance cancer care and research
Be at the forefront in early drug development in APAC and join us in this transformative event in novel cancer therapeutics
Join Scientific Co-Chairs Mariam Jamal-Hanjani, Lisa Derosa, and Joaquin Mateo in shaping the future of precision oncology through collaboration and innovation at MAP 2025, 15-16 Sept., Paris, France
Make sure your presentations include the latest ESMO Guidelines recommendations!
This Guideline has just been updated with the latest recommendations and algorithms in an interactive format
Online application is open until 15 May 2025
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
The combination of lenvatinib plus everolimus improved progression-free survival in the LenCabo trial, but toxicity must be carefully assessed
In the evERA BC trial, giredestrant plus everolimus led to a prolonged progression-free survival
In early phase studies, IAG933 and VT3989 led to encouraging disease control rates with manageable toxicity
The promises of a tumour-agnostic oncology are still challenged by conventional clinical trial design and regulatory processes
Findings from latest research reflect emerging opportunities in oncology to refine treatments by challenging current paradigms of care
Two studies fail to meet their primary endpoints, reinforcing the need to improve the sensitivity of ctDNA testing before it enters the clinic
Positive initial overall survival data were, however, attenuated and may not be clinically meaningful in a longer-term analysis
In the IMvigor011 trial, ctDNA positivity was reported to be strongly predictive of adjuvant immunotherapy benefit in muscle-invasive bladder cancer
Novel strategies are offering the possibility of extended patient survival and durable disease control
Evidence for efficacy is based on the results from the CHECKMATE-8HW study
New indication concerns a combination with etoposide and platinum chemotherapy for the first-line treatment of adult patients with extensive-stage SCLC
Findings from the analysis of TRACERx and MSK-IMPACT studies
Findings from the CoPPO study
A valuable tool for point-of-care clinical decision-making in patients with non-Hodgkin lymphoma
Evidence for efficacy is based on the results from the NIAGARA study
Findings from the BARCODE1 study
Trabectedin Accord is a generic of Yondelis, which has been authorised in the EU since 2007
Findings from the API-CAT study
ESMO Breast Cancer 2025 will take place between 14-17 May in Munich, Germany, bringing together international experts to present and discuss the latest advances in breast cancer research and care
The European Lung Cancer Congress 2025 is the event dedicated to the prevention, diagnosis, and management of thoracic malignancies
The ESMO Sarcoma and Rare Cancers Congress 2025, to be held from 20-22 March in Lugano, Switzerland, will be the convergence point for world-renowned experts to present and discuss developments in the diagnosis and treatment of rare solid tumours, going through their peculiar biology and molecular classification, while also addressing the methodological, organisational, and policy challenges that characterise this oncological area and its high unmet needs
Experts predict death rates from all cancers for the EU and UK for 2025
The ESMO Targeted Anticancer Therapies Congress 2025 will showcase state-of-the-art and the latest advancements in new drug development, with focus on new targets, tumour-agnostic drug development, the role of artificial intelligence in drug development, radiotheranostics and cell therapies for solid tumours
The ESMO Immuno-Oncology Congress 2024 will take place in Geneva, Switzerland, from December 11-13, with an option to attend virtually. Leading experts will present and discuss the research advancements in the rapidly evolving field of immuno-oncology
The ESMO Asia Congress 2024 is the annual event dedicated to multidisciplinary oncology in the Asian region
The Molecular Analysis for Precision Oncology Congress 2024 (MAP) is the appointment where globally recognised experts will present and discuss research in precision medicine, technologies for cancer profiling, mechanisms driving tumour expansion, metastatic dissemination, clonal evolution, and biomarker-driven development of targeted therapeutics
Immunotherapy, which works by enabling the body’s immune system to recognise and destroy cancer cells improves long-term overall survival in patients with advanced melanoma in results from large international studies reported at ESMO 2024
It is with great sadness that ESMO has learnt of the passing of Maurice Schneider, one of the Society’s co-founders
At a time when innovation is more critical than ever in oncology, ESMO is determined to ensure that regulatory developments support, rather than hinder, cancer research in Europe
The European Society for Medical Oncology (ESMO) announced today that the recipient of the 2025 ESMO Breast Cancer Award is Gabriel N. Hortobagyi, Professor of Medicine in the Department of Breast Medical Oncology at The University of Texas M.D. Anderson Cancer Center, USA
The European Society for Medical Oncology (ESMO) announced today that the recipient of the 2025 Heine H. Hansen Award is Keith Kerr, Consultant Pathologist for NHS Grampian and Honorary Chair in Pulmonary Pathology at the University of Aberdeen in Scotland
Burnout is an increasingly pressing concern for the oncology community
This year marks the 10th anniversary of the ESMO Women for Oncology (W4O) Committee, a decade-long commitment to advancing gender equity in oncology
ESMO reaffirms its commitment to working with EU stakeholders to maximize the potential of the Beating Cancer Plan
Bringing together cancer patient advocates from around the world will create a bridge between diverse experiences and perspectives and help secure the optimisation of patient care worldwide
The nomination process for the 2025 ESMO Society Awards is now open
The combination of lenvatinib plus everolimus improved progression-free survival in the LenCabo trial, but toxicity must be carefully assessed
In the evERA BC trial, giredestrant plus everolimus led to a prolonged progression-free survival
In early phase studies, IAG933 and VT3989 led to encouraging disease control rates with manageable toxicity
The promises of a tumour-agnostic oncology are still challenged by conventional clinical trial design and regulatory processes
Findings from latest research reflect emerging opportunities in oncology to refine treatments by challenging current paradigms of care
Two studies fail to meet their primary endpoints, reinforcing the need to improve the sensitivity of ctDNA testing before it enters the clinic
Positive initial overall survival data were, however, attenuated and may not be clinically meaningful in a longer-term analysis
In the IMvigor011 trial, ctDNA positivity was reported to be strongly predictive of adjuvant immunotherapy benefit in muscle-invasive bladder cancer
Novel strategies are offering the possibility of extended patient survival and durable disease control
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
Germany
Czech Republic
Republic of Singapore
United Kingdom
Switzerland
France
Denmark
Spain
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
ESMO Examination 2025 will be held on Saturday 18 October during the ESMO Congress 2025.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
